Active Ingredient History
Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitromodels, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown. Sulfasalazine is used for the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. Sulfasalazine is marketed under the trade name Azulfidine among others. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Administration, Oral (Phase 1)
Adrenal Cortex Hormones (Phase 3)
Arthritis, Juvenile (Phase 4)
Arthritis, Psoriatic (Phase 4)
Asthma (Phase 3)
Axial Spondyloarthritis (Phase 4)
Breast Neoplasms (Phase 1/Phase 2)
Cholangitis, Sclerosing (Phase 2)
Chronic Pain (Early Phase 1)
Colorectal Neoplasms (Phase 3)
Coronary Disease (Phase 2)
Diarrhea (Phase 3)
Drug Combinations (Phase 4)
Drug Interactions (Phase 1)
Endothelial Cells (Phase 4)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 1)
Healthy Volunteers (Phase 1)
Heart Disease Risk Factors (Phase 4)
Intestinal Neoplasms (Phase 3)
Intestinal Obstruction (Phase 1)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Lichen Planus, Oral (Phase 3)
Magnetic Resonance Imaging (Phase 1)
Methotrexate (Phase 4)
Neoplasms (Phase 3)
Pain (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 1)
Premature Birth (Phase 2)
Psoriasis (Phase 2)
Pulmonary Arterial Hypertension (Phase 1/Phase 2)
Spondylitis, Ankylosing (Phase 4)
Still's Disease, Adult-Onset (Phase 2)
Substance Withdrawal Syndrome (Phase 3)
Vascular Stiffness (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue